Anaplastic Large Cell Lymphoma (ALCL)

In January 2011, the American Food and Drug Administration (FDA) issued a communication to inform health care providers and the public about a possible association between breast implants and a type of anaplastic large cell lymphoma (ALCL).

Information published by the FDA is available in the following web pages:

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)  (March 2017)

FDA Medical Device Safety Communication: Reports of Anaplastic Large Cell Lymphoma (ALCL) in Women with Breast Implants (January 26, 2011)

Questions and Answers about Anaplastic Large Cell Lymphoma (ALCL)

Further information from the Canadian Society of Plastic Surgeons:

ALCL Letter to CSPS Membership (December 3, 2019)

ALCL Letter to CSPS Membership (August 12, 2019)

ALCL Letter to CSPS Membership (July 30, 2019)

ALCL Letter to CSPS Membership (May 30, 2019)

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines):  T-Cell Lymphomas (December 7, 2016)

NCCN Consensus Guidelines for Diagnosis and Management of BIA ALCL (November 2016)

Letter to CSPS Members – October 27, 2016

Letter to CSPS Members – November 4, 2015

MD Anderson Cancer Center – Frequently asked Questions – November 4, 2015